HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.

@article{Strati2014HCVADPI,
  title={HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.},
  author={Paolo Strati and Hagop Kantarjian and Deborah Thomas and Susan M O'Brien and Sergej Naumovich Konoplev and Jeffrey L. Jorgensen and Raja Luthra and Lynne V. Abruzzo and Elias J Jabbour and Alfonso Quint{\'a}s-Cardama and Gautam Borthakur and Stefan H. Faderl and Farhad Ravandi and Jorge Cort{\'e}s},
  journal={Cancer},
  year={2014},
  volume={120 3},
  pages={
          373-80
        }
}
BACKGROUND Chronic myeloid leukemia (CML) may progress to blast phase (BP) at the rate of 1% to 1.5% per year. With the use of single-agent tyrosine kinase inhibitors, median overall survival ranges between 7 and 11 months. METHODS The outcome was analyzed for 42 patients with lymphoid BP-CML who were treated with hyperfractionated cyclophosphamide, vincristine, Adriamycin, dexamethasone (HCVAD) plus imatinib or dasatinib. RESULTS Complete hematological response was achieved in 90% of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Management of chronic myeloid leukemia in blast crisis

  • Annals of Hematology
  • 2015
VIEW 3 EXCERPTS
HIGHLY INFLUENCED

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Management of CML-blast crisis.

  • Best practice & research. Clinical haematology
  • 2016
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Blastic phase of chronic myelogenous leukemia

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

The blast phase of chronic myeloid leukaemia.

  • Best practice & research. Clinical haematology
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL